Multiple myeloma triplet therapies: baseline characteristics and control groups

Affiliations

¹ IMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Navitas Clinic Kawasaki, Kanagawa, Japan.

Comment

Motoharu Shibusawa et al. Lancet. 2021.

. 2021 May 1;397(10285):1621.

doi: 10.1016/S0140-6736(21)00270-1.

¹ IMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Navitas Clinic Kawasaki, Kanagawa, Japan.

No abstract available

Conflict of interest statement

TT reports personal fees from Medical Network Systems and Bionics. MS declares no competing interests.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Grosicki S, et al. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.